News in brief
Invisibility cloaks and a climate dashboard: News from the College
Here’s a batch of fresh news and announcements from across Imperial.
Stories written by Andrew Scheuber
Global Science
Pandemic shows it’s time to 'protect and nurture global science' - Alice Gast
The COVID-19 crisis ensured that the "globalisation of research is...central to our way of life", writes President Alice Gast in the Financial Times.
Brazil variant
More transmissible and evasive SARS-CoV-2 variant growing rapidly in Brazil
The P.1 lineage of the SARS-CoV-2 variant first observed in Brazil has driven a second wave of infections even in a region hit hard by the first wave.
Vaccine future
Imperial vaccine tech to target COVID mutations and booster doses
Imperial is focusing its RNA vaccine technology to target SARS-CoV-2 mutations, boosters and thermostability rather than an immediate efficacy trial.
Hospital crisis
Staff 'need clearer guidance' as COVID overwhelms ICUs
Hospital staff are receiving insufficient support as they make agonising choices about who does and does not receive care, writes Dr Katharina Hauck.
NEW VARIANT INSIGHTS
New COVID-19 variant growing rapidly in England
The new SARS-CoV-2 variant is growing rapidly, is more transmissible than other variants, and affecting a greater proportion of under 20s.
Replicating modelling
BMJ study confirms Imperial COVID-19 projections
An Edinburgh University analysis of Imperial's Report 9 COVID-19 modelling has confirmed the group's key projections from March.
Coronavirus test rollout
90 minute COVID-19 tests: Government orders 5.8 million DnaNudge kits
The government has placed a £161 million order for 5.8 million high-speed DnaNudge COVID-19 test kits to be used in NHS hospitals from September.
12
New wave fears
Prepare now for winter COVID-19 peak, warn infectious disease experts
The UK must prepare now for a potential new wave of coronavirus infections this winter, says a new Academy of Medical Sciences report.
Coronavirus vaccine trial
COVID-19 trial progresses, as 'cautious optimism' grows for RNA vaccine
More than 300 participants have been screened for Imperial's COVID-19 vaccine trial as its lead speaks of "cautious optimism".
3
